Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Emergent BioSolutions Inc.NYSE: EBS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $23.5M fell 7.5% year over year, ahead of the -11.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -12.6% a year.
Context
- Depreciation & amortization amounted to 12.9% of revenue in FY2025, up 2.5 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -7.5% holds above the trailing-twelve-month pace of -11.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 95.8M USD
- Year-over-year change
- -11.9%
- 4-year CAGR
- -6.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.8M | -11.9% |
| FY2024 | 2024-12-31 | 108.8M | -13.0% |
| FY2023 | 2023-12-31 | 125.1M | -12.7% |
| FY2022 | 2022-12-31 | 143.3M | +15.8% |
| FY2021 | 2021-12-31 | 123.8M | — |
Depreciation & Amortization vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.7% is the 9th highest of 11, against a peer median of +9.5%.
- Depreciation & amortization amounts to 13.9% of revenue for EBS, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $93.9M USD | -11.7% | -12.6% | 13.9% | |
| LTM Mar 2026 | CA$56.2M CAD | -0.2% | +5.9% | 6.0% | |
| LTM Mar 2026 | $30.95M USD | +45.2% | +35.9% | 6.0% | |
| LTM Mar 2026 | $2.41M USD | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $1.5M USD | +328.5% | -40.6% | 0.4% | |
| LTM Mar 2026 | $856K USD | +258.2% | +6.4% | 1.5% | |
| LTM Mar 2026 | $577.25K USD | +7.8% | +2.8% | 0.6% | |
| LTM Mar 2026 | $522K USD | -19.7% | -38.8% | 1.0% | |
| LTM Mar 2026 | $481K USD | +11.1% | -33.4% | — | |
| LTM Mar 2026 | $179K USD | -14.4% | -13.2% | — | |
| LTM Mar 2026 | $112K USD | +33.3% | -34.1% | — | |
| Peer median (excluding EBS) | — | +9.5% | -5.2% | 1.0% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 230.9M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Depreciation & Amortization | 123.8M | 143.3M | 125.1M | 108.8M | 95.8M |
| Deferred Income Tax | 46.9M | (28.6M) | (8.9M) | (5.5M) | (4M) |
| Stock-Based Compensation | 42.4M | 45.1M | 23.1M | 18M | 16.2M |
| Change in Working Capital | (156.4M) | (2.1M) | (70.3M) | 88.7M | (22.4M) |
| Accounts Receivables | (48.2M) | 118.1M | (21.6M) | (24.4M) | 25.5M |
| Inventory | (44M) | (57.1M) | 600K | (24.5M) | (30.3M) |
| Accounts Payables | (2.5M) | (14M) | 10.6M | (33M) | (8.4M) |
| Other Working Capital | (61.7M) | (49.1M) | (59.9M) | 170.6M | (9.2M) |
| Other Non-Cash Items | 33.5M | 19.8M | 485.2M | 39.3M | 32.4M |
| Operating Cash Flow | 321.1M | (34.1M) | (206.3M) | 58.7M | 170.6M |
| Capital Expenditures | (225M) | (115.8M) | (51.6M) | (22.9M) | (13.8M) |
| Acquisitions (Net) | 0 | 0 | 270.2M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (265.5M) | (6.3M) | 148.1M | 83.2M |
| Investing Cash Flow | (225M) | (381.3M) | 212.3M | 125.2M | 69.4M |
| Debt Repayment | (35.9M) | 564.2M | (543.4M) | (198.4M) | (112.5M) |
| Common Stock Issued | 0 | 0 | 8.4M | 9.3M | 2.2M |
| Common Stock Repurchased | (106M) | (82.1M) | 0 | 0 | (24.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 900K | (900K) | (700K) | (900K) | (1.4M) |
| Financing Cash Flow | (141M) | 481.2M | (535.7M) | (190M) | (136.6M) |
| Effect of Forex Changes | (300K) | 500K | (1.2M) | 0 | 100K |
| Net Change in Cash | (45.2M) | 66.3M | (530.9M) | (6.1M) | 103.5M |
| Free Cash Flow | 96.1M | (149.9M) | (257.9M) | 35.8M | 156.8M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.